drugset / Trial / NCT00958386
Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)
Phase 2
Completed
61 enrolled
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Amgen · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the efficacy and safety of the combination of Panitumumab with Irinotecan in patients with Wild-Type KRAS metastatic colorectal cancer refractory to irinotecan based chemotherapy.
Timeline
- Start
- 2009-08
- Primary completion
- 2014-07
- Completion
- 2014-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 180 mg/m2 | — |
| Subject | Panitumumab | Monoclonal antibody | 6 mg/kg | Intravenous |